All In Biotech

Drug Trial Radar · NCT01358578

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,306

Actual

Start

Jun 2011

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

Conditions

  • Chronic Plaque Psoriasis

Interventions

  • PlaceboDrug

    Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

  • secukinumab (AIN457)Drug

    secukinumab (AIN457) 150mg or 300mg subcutaneous

  • etanerceptDrug

    etanercept 50mg subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .Time frame: 12 wks
  2. Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12Time frame: 12 wks

Locations

152 sites in 23 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    High Point, North Carolina

  • Novartis Investigative Site

    Warren, Ohio

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Johnston, Rhode Island

  • Novartis Investigative Site

    Charleston, South Carolina

  • Novartis Investigative Site

    Kingsport, Tennessee

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Norfolk, Virginia

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires F.D., Argentina

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    Carlton, Victoria, Australia

  • Novartis Investigative Site

    East Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Surrey, British Columbia, Canada

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada

  • Novartis Investigative Site

    Markham, Ontario, Canada

  • Novartis Investigative Site

    Richmond Hil, Ontario, Canada

  • Novartis Investigative Site

    Waterloo, Ontario, Canada

  • Novartis Investigative Site

    Sainte-Foy, Quebec, Canada

  • Novartis Investigative Site

    Barranquilla, Colombia

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Bucaramanga, Colombia

  • Novartis Investigative Site

    Alexandria, Egypt

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.